Ellias' significant experience and expertise in T1D will gre...
Ellias' significant experience and expertise in T1D will greatly benefit SAB's Board of Directors, stated Samuel J. Reich, Executive Chairman of SAB. Acknowledging the company's promising position in T1D, Ellias expressed her enthusiasm for joining SAB's Board of Directors.
Press Release: SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment